Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Abstract

The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies becomes very poor, and the retreatment with previously adopted and effective therapy, although unpredictable, could be an effective option. In this report, we describe the clinical history of a patient, previously treated with 9 lines of therapy, refractory to bortezomib and IMIDs, for whom the retreatment with bendamustine resulted in a stable disease with good quality of life.

Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?

“…18 F-FDG-PET/CT showed no substantially changes in lymphadenomegaly volumes. The frontline regimen was thus interrupted and switched to bendamustine-rituximab (rituximab 375 mg/m 2 on day 1 and bendamustine 90 mg/m 2 on days 1–2) supported by growth factors (pegfilgrastim 6 mg on day 4 [ 4 – 9 ] and erythropoietin β 30,000 U/wk, administered from the first cycle onwards), every 28 days for 6 courses. This regimen was well tolerated, patient compliance was optimal, there were no delays in administration and no infectious episodes.…”